Shire to purchase Jerini for €349M

07/6/2008 | (India) · Bloomberg

U.K. drug company Shire will pay €349 million in cash to acquire Jerini, maker of Firazyr, a treatment for hereditary angioedema. Shire is working with the German drugmaker to boost the efficacy of the medicine after it failed in a late-stage study to outperform placebo. Firazyr is expected to generate as much as $400 million a year once it reaches the European market.

View Full Article in: (India) · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA